The study population will include cancer patients (ICD-10: C00-D49) aged 18 or older. Chemotherapy-Induced Peripheral Neuropathy (CIPN), Risk Prediction, Cytotoxic Agents, toxicity, Clinical Prediction Model.
Conditions
Interventions
Patients with chemotherapy-unduced peripheral neuropahaty following chemotherapy treatment ,Patients with no chemotherapy-unduced peripheral neuropahatyfollowing chemotherapy treatment
Supportive Care,Supportive Care
Peripheral neuropathy patients,No peripheral neuropathy patients
Sponsors
Payap University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Patients with a diagnosis of cancer (ICD-10: C00-D49). 2. Age 18 years or older. 3. Received chemotherapy with Taxanes, Platinum compounds, or Vinca alkaloids. 4. Received treatment at the cancer center in Chiang Mai between 2019-2024.
Exclusion criteria
Exclusion criteria: 1. Incomplete medical records. 2. Patients with pre-existing peripheral neuropathy. 3. Patients who withdrew from the study or were lost to follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peripheral neuropathy February 28th, 2025 Grading regarding to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 | — |
Secondary
| Measure | Time frame |
|---|---|
| Predictive performance of model March 31st, 2025 area under the Receiver Operating Characteristic curve (AUC-ROC),Predictive performance March31st, 2025 slope of calibration plot, p-value of Hosmer's-Lemshow's goodness-of-fit test,Internal validation March31st,2025 area under the Receiver Operating Characteristic curve (AUC-ROC) from Cross validation test,Model Decision Analysis March31st,2025 Decision curve analysis (DCA) | — |
Countries
Thailand
Contacts
Public ContactNatharin Phattayanon
Faculty of Pharmacy, Payap University.
Outcome results
None listed